Cannabis descheduling not one of 'core priorities' for pharma giant

A pharmaceutical giant that once developed marijuana-based medicines won't be advocating for the descheduling of cannabis anytime soon. Indianapolis-based Eli Lilly & Co. opposes a shareholder proposal seeking Lilly to proclaim support of marijuana descheduling, according to a U.S. Securities ...

read more here
Delivered by @can_nab_is